MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (1720)	10/31/2006 4:12:26 PM
From: tuck	of 1826

>>MGI PHARMA Announces Specific J Code Assignment for Dacogen(TM) Tuesday October 31, 4:01 pm ET MINNEAPOLIS--(BUSINESS WIRE)--MGI PHARMA, INC. (NASDAQ:MOGN - News), a biopharmaceutical company focused in oncology and acute care, today announced that the Centers for Medicare and Medicaid Services (CMS) have assigned a specific J-code for Dacogen(TM) (decitabine) for Injection. Effective January 1, 2007, code J0894 will enable providers to obtain reimbursement for Dacogen. The Healthcare Common Procedure Coding System (HCPCS) National Panel has reviewed Dacogen's application submitted to CMS and has decided to assign a new specific J code for use by all payers. The HCPCS National Panel is made up of members of the private insurance industry, Medicaid and Medicare. "This specific J-code designation will allow providers to submit Dacogen claims electronically, which should reduce the administrative burden and enable more rapid reimbursement," said Eric P. Loukas, Executive Vice President and Chief Operating Officer of MGI PHARMA. "I would like to thank our medical and reimbursement teams for their efforts, which led to this decision within six months of the Dacogen commercial launch."<< snip Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next